Inhaled PLGA particles of prostaglandin E1 ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 1655-1667

  Gupta, Vivek ^a,e   Gupta, Nilesh ^a   Shaik, Imam H ^a   Mehvar, Reza ^a   Nozik Grayck, Eva ^b   McMurtry, Ivan F ^c   Oka, Masahiko ^c   Komatsu, Masanobu ^d   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Children's Hospital Colorado   (United States)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^d BURNHAM INSTITUTE   (United States)

^e University of California   (United States)

Author keywords

controlled release; monocrotaline; PLGA microparticles; prostaglandin E1; pulmonary hypertension

Indexed keywords

GELATINASE A; POLYLACTIC ACID; POLYMER; PROSTAGLANDIN E1; VON WILLEBRAND FACTOR; DELAYED RELEASE FORMULATION; DRUG CARRIER; GELATINASE B; LACTIC ACID; MMP2 PROTEIN, RAT; MMP9 PROTEIN, RAT; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; LUNG ARTERY PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; THROMBOCYTE AGGREGATION; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INHALATIONAL DRUG ADMINISTRATION; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; ALPROSTADIL; ANIMALS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG CARRIERS; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LACTIC ACID; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS; VON WILLEBRAND FACTOR;

EID: 84877256054     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300426u     Document Type: Article

References (59)

1. Gupta, V.; Ahsan, F. Inhalational therapy for pulmonary arterial hypertension: current status and future prospects Crit. Rev. Ther. Drug Carrier Syst. 2010, 27 (4) 313-70
2. Rich, S.; Dantzker, D. R.; Ayres, S. M.; Bergofsky, E. H.; Brundage, B. H.; Detre, K. M.; Fishman, A. P.; Goldring, R. M.; Groves, B. M.; Koerner, S. K. Primary pulmonary hypertension. A national prospective study Ann. Intern. Med. 1987, 107 (2) 216-23
3. Martin, K. B.; Klinger, J. R.; Rounds, S. I. Pulmonary arterial hypertension: new insights and new hope Respirology 2006, 11 (1) 6-17
4. Weissmann, N.; Akkayagil, E.; Quanz, K.; Schermuly, R. T.; Ghofrani, H. A.; Fink, L.; Hanze, J.; Rose, F.; Seeger, W.; Grimminger, F. Basic features of hypoxic pulmonary vasoconstriction in mice Respir. Physiol. Neurobiol. 2004, 139 (2) 191-202
5. Corris, P. A. Alternatives to lung transplantation: treatment of pulmonary arterial hypertension Clin. Chest Med. 2011, 32 (2) 399-410
6. Goyal, P.; Weissmann, N.; Grimminger, F.; Hegel, C.; Bader, L.; Rose, F.; Fink, L.; Ghofrani, H. A.; Schermuly, R. T.; Schmidt, H. H.; Seeger, W.; Hanze, J. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species Free Radical Biol. Med. 2004, 36 (10) 1279-88
7. Ghofrani, H. A.; Friese, G.; Discher, T.; Olschewski, H.; Schermuly, R. T.; Weissmann, N.; Seeger, W.; Grimminger, F.; Lohmeyer, J. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension Eur. Respir. J. 2004, 23 (2) 321-6
8. Schermuly, R. T.; Kreisselmeier, K. P.; Ghofrani, H. A.; Samidurai, A.; Pullamsetti, S.; Weissmann, N.; Schudt, C.; Ermert, L.; Seeger, W.; Grimminger, F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension Circ. Res. 2004, 94 (8) 1101-8
9. Gomberg-Maitland, M.; Preston, I. R. Prostacyclin therapy for pulmonary arterial hypertension: new directions Semin. Respir. Crit. Care Med. 2005, 26 (4) 394-401
10. Galie, N.; Manes, A.; Negro, L.; Palazzini, M.; Bacchi-Reggiani, M. L.; Branzi, A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur. Heart J. 2009, 30 (4) 394-403
11. Humbert, M.; Sitbon, O.; Chaouat, A.; Bertocchi, M.; Habib, G.; Gressin, V.; Yaici, A.; Weitzenblum, E.; Cordier, J. F.; Chabot, F.; Dromer, C.; Pison, C.; Reynaud-Gaubert, M.; Haloun, A.; Laurent, M.; Hachulla, E.; Simonneau, G. Pulmonary arterial hypertension in France: results from a national registry Am. J. Respir. Crit. Care Med. 2006, 173 (9) 1023-30
12. Hyduk, A.; Croft, J. B.; Ayala, C.; Zheng, K.; Zheng, Z. J.; Mensah, G. A. Pulmonary hypertension surveillance - United States, 1980-2002 MMWR Surveillance Summit 2005, 54 (5) 1-28
13. Ghofrani, H. A.; Voswinckel, R.; Reichenberger, F.; Olschewski, H.; Haredza, P.; Karadas, B.; Schermuly, R. T.; Weissmann, N.; Seeger, W.; Grimminger, F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study J. Am. Coll. Cardiol. 2004, 44 (7) 1488-96
14. Gupta, V.; Ahsan, F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE, a pulmonary selective vasodilator Int. J. Pharmaceutics 2011, 413 (1-2) 51-62
15. Gupta, V.; Davis, M.; Hope-Weeks, L. J.; Ahsan, F. PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-beta-cyclodextrin (PGE1-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH) Pharm. Res. 2011, 28 (7) 1733-49
16. Gupta, V.; Rawat, A.; Ahsan, F. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension J. Pharm. Sci. 2010, 99 (4) 1774-89
17. Kloeze, J. Relationship between chemical structure and platelet-aggregation activity of prostaglandins Biochim. Biophys. Acta 1969, 187 (3) 285-92
18. Levin, G.; Duffin, K. L.; Obukowicz, M. G.; Hummert, S. L.; Fujiwara, H.; Needleman, P.; Raz, A. Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2 Biochem. J. 2002, 365 (Pt 2) 489-96
19. Salvatori, R.; Guidon, P. T., Jr.; Rapuano, B. E.; Bockman, R. S. Prostaglandin E1 inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts Endocrinology 1992, 131 (1) 21-8
20. Zurier, R. B.; Quagliata, F. Effect of prostaglandin E 1 on adjuvant arthritis Nature 1971, 234 (5327) 304-5
21. Meyer, J.; Theilmeier, G.; Van Aken, H.; Bone, H. G.; Busse, H.; Waurick, R.; Hinder, F.; Booke, M. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure Anesth. Analg. 1998, 86 (4) 753-8
22. Kunimoto, F.; Arai, K.; Isa, Y.; Koyano, T.; Kadoi, Y.; Saito, S.; Goto, F. A comparative study of the vasodilator effects of prostaglandin E1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome Anesth. Analg. 1997, 85 (3) 507-13
23. Shen, J.; He, B.; Wang, B. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension Chest 2005, 128 (2) 714-9
24. Sood, B. G.; Delaney-Black, V.; Aranda, J. V.; Shankaran, S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial Pediatr. Res. 2004, 56 (4) 579-85
25. Cox, J. W.; Andreadis, N. A.; Bone, R. C.; Maunder, R. J.; Pullen, R. H.; Ursprung, J. J.; Vassar, M. J. Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome Am. Rev. Respir. Dis. 1988, 137 (1) 5-12
26. van Heerden, P. V.; Caterina, P.; Filion, P.; Spagnolo, D. V.; Gibbs, N. M. Pulmonary toxicity of inhaled aerosolized prostacyclin therapy - an observational study Anaesth. Intensive Care 2000, 28 (2) 161-6
27. Edwards, D. A.; Hanes, J.; Caponetti, G.; Hrkach, J.; Ben-Jebria, A.; Eskew, M. L.; Mintzes, J.; Deaver, D.; Lotan, N.; Langer, R. Large porous particles for pulmonary drug delivery Science 1997, 276 (5320) 1868-71
28. Cowan, K. N.; Heilbut, A.; Humpl, T.; Lam, C.; Ito, S.; Rabinovitch, M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor Nat. Med. 2000, 6 (6) 698-702
29. Stinger, R. B.; Iacopino, V. J.; Alter, I.; Fitzpatrick, T. M.; Rose, J. C.; Kot, P. A. Catheterization of the pulmonary artery in the closed-chest rat J. Appl. Physiol. 1981, 51 (4) 1047-50
30. Crossno, J. T., Jr.; Garat, C. V.; Reusch, J. E.; Morris, K. G.; Dempsey, E. C.; McMurtry, I. F.; Stenmark, K. R.; Klemm, D. J. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292 (4) L885-97
31. Van Rheen, Z.; Fattman, C.; Domarski, S.; Majka, S.; Klemm, D.; Stenmark, K. R.; Nozik-Grayck, E. Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling Am. J. Respir. Cell Mol. Biol. 2011, 44 (4) 500-8
32. Guignabert, C.; Raffestin, B.; Benferhat, R.; Raoul, W.; Zadigue, P.; Rideau, D.; Hamon, M.; Adnot, S.; Eddahibi, S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats Circulation 2005, 111 (21) 2812-9
33. Patel, B.; Gupta, V.; Ahsan, F. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin J. Controlled Release 2012, 162 (2) 310-20
34. Gomez-Arroyo, J. G.; Farkas, L.; Alhussaini, A. A.; Farkas, D.; Kraskauskas, D.; Voelkel, N. F.; Bogaard, H. J. The monocrotaline model of pulmonary hypertension in perspective Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302 (4) L363-9
35. Todd, L.; Mullen, M.; Olley, P. M.; Rabinovitch, M. Pulmonary toxicity of monocrotaline differs at critical periods of lung development Pediatr. Res. 1985, 19 (7) 731-7
36. Hilliker, K. S.; Bell, T. G.; Roth, R. A. Pneumotoxicity and thrombocytopenia after single injection of monocrotaline Am. J. Physiol. 1982, 242 (4) H573-9
37. Price, L. C.; Wort, S. J.; Finney, S. J.; Marino, P. S.; Brett, S. J. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review Crit. Care 2010, 14 (5) R169
38. Garcia-Contreras, L.; Sethuraman, V.; Kazantseva, M.; Godfrey, V.; Hickey, A. J. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig J. Antimicrob. Chemother. 2006, 58 (5) 980-6
39. Jeong, Y. I.; Song, J. G.; Kang, S. S.; Ryu, H. H.; Lee, Y. H.; Choi, C.; Shin, B. A.; Kim, K. K.; Ahn, K. Y.; Jung, S. Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid Int. J. Pharmaceutics 2003, 259 (1-2) 79-91
40. Lombry, C.; Edwards, D. A.; Preat, V.; Vanbever, R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286 (5) L1002-8
41. Harush-Frenkel, O.; Bivas-Benita, M.; Nassar, T.; Springer, C.; Sherman, Y.; Avital, A.; Altschuler, Y.; Borlak, J.; Benita, S. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery Toxicol. Appl. Pharmacol. 2010, 246 (1-2) 83-90
42. Kato, S.; Sugimura, H.; Kishiro, I.; Machida, M.; Suzuki, H.; Kaneko, N. Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension Exp. Lung Res. 2002, 28 (4) 265-73
43. Schermuly, R. T.; Yilmaz, H.; Ghofrani, H. A.; Woyda, K.; Pullamsetti, S.; Schulz, A.; Gessler, T.; Dumitrascu, R.; Weissmann, N.; Grimminger, F.; Seeger, W. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension Am. J. Respir. Crit. Care Med. 2005, 172 (3) 358-63
44. Howell, K.; Preston, R. J.; McLoughlin, P. Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation J. Physiol. 2003, 547 (Pt 1) 133-45
45. Hyvelin, J. M.; Howell, K.; Nichol, A.; Costello, C. M.; Preston, R. J.; McLoughlin, P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Circ. Res. 2005, 97 (2) 185-91
46. Stenmark, K. R.; Mecham, R. P. Cellular and molecular mechanisms of pulmonary vascular remodeling Annu. Rev. Physiol. 1997, 59, 89-144
47. Dell, K.; Bohler, T.; Gaedeke, J.; Budde, K.; Neumayer, H. H.; Waiser, J. Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells Cytokine 2003, 22 (6) 189-93
48. Schneider, A.; Thaiss, F.; Rau, H. P.; Wolf, G.; Zahner, G.; Jocks, T.; Helmchen, U.; Stahl, R. A. Prostaglandin E1 inhibits collagen expression in anti-thymocyte antibody-induced glomerulonephritis: possible role of TGF beta Kidney Int. 1996, 50 (1) 190-9
49. Luscher, T. F.; Barton, M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs Circulation 2000, 102 (19) 2434-40
50. Lopes, A. A.; Maeda, N. Y.; Aiello, V. D.; Ebaid, M.; Bydlowski, S. P. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension Chest 1993, 104 (5) 1455-60
51. Sadler, J. E. Biochemistry and genetics of von Willebrand factor Annu. Rev. Biochem. 1998, 67, 395-424
52. Veyradier, A.; Nishikubo, T.; Humbert, M.; Wolf, M.; Sitbon, O.; Simonneau, G.; Girma, J. P.; Meyer, D. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension Circulation 2000, 102 (20) 2460-2
53. Lepetit, H.; Eddahibi, S.; Fadel, E.; Frisdal, E.; Munaut, C.; Noel, A.; Humbert, M.; Adnot, S.; D'Ortho, M. P.; Lafuma, C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension Eur. Respir. J. 2005, 25 (5) 834-42
54. Shankavaram, U. T.; Lai, W. C.; Netzel-Arnett, S.; Mangan, P. R.; Ardans, J. A.; Caterina, N.; Stetler-Stevenson, W. G.; Birkedal-Hansen, H.; Wahl, L. M. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation J. Biol. Chem. 2001, 276 (22) 19027-32
55. Gutierrez, F. R.; Lalu, M. M.; Mariano, F. S.; Milanezi, C. M.; Cena, J.; Gerlach, R. F.; Santos, J. E.; Torres-Duenas, D.; Cunha, F. Q.; Schulz, R.; Silva, J. S. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection J. Infect. Dis. 2008, 197 (10) 1468-76
56. Giannelli, G.; Iannone, F.; Marinosci, F.; Lapadula, G.; Antonaci, S. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension Curr. Med. Res. Opin. 2005, 21 (3) 327-32
57. Palei, A. C.; Zaneti, R. A.; Fortuna, G. M.; Gerlach, R. F.; Tanus-Santos, J. E. Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism Angiology 2005, 56 (5) 611-7
58. Lai, Y. L.; Law, T. C. Chronic hypoxia- and monocrotaline-induced elevation of hypoxia-inducible factor-1 alpha levels and pulmonary hypertension J. Biomed. Sci. 2004, 11 (3) 315-21
59. Kunihara, M.; Tsuchida, K.; Kaneko, K.; Suga, H.; Hasegawa, T.; Mochizuki, S.; Kawai, K.; Shiga, A.; Yamaguchi, T. Inhibitory effects of alprostadil (prostaglandin E1) incorporated in lipid microspheres of soybean oil on intimal hyperplasia following balloon injury in rabbits Arzneimittelforschung 2002, 52 (5) 358-64